Citius Oncology Inc (CTOR)

I'm back in at 1.60

And I'll probably avg down every dime it falls.

It's probably a question of when the shorts decide to cover.

PR released today:

CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius Oncology, Inc
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

https://www.prnewswire.com/news-releases/citius-oncology-expands-distribution-network-for-lymphir-with-execution-of-distribution-services-agreement-with-cencora-302502730.html

S-1/A out: Priced at $2.82

Geez, when I said "under $2.00" I didn't mean "today." Now I'm thinking it's going under $1.50 when they price the offering, UNLESS they wait for product launch to set the price.

I plan to buy back in, but not yet. Game of musical chairs.

CTOR is being shorted heavily just like CTXR, IMO.

New S-1, doesn't name the price but they're going to the well for CTOR, fresh on the heels of the recent CTXR dilution. $15 million again.

https://www.otcmarkets.com/filing/html?id=18609946&guid=lHi-k6_mgTJjJth

Interesting to see how low CTOR goes when they price the offering. Under $2 seems possible.

I plan to get back in, but when? Hoping it gets oversold the way CTXR was oversold.

Perfect buying opportunity right here at the price of $2.85.

Risk has dropped significantly.

I'm out until the dust settles.

That was a nice run.

Finger on the trigger for the launch -- there could be a nice squeeze then.

Best of luck to all who are holding!

NASD short interest as of 06/30: 366,000, which is about 9% of the float that's not in the hands of the insiders.

Possible short squeeze on news. Until then.....

https://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Does anyone have live short interest data? Live short data would be more valuable than screen prints of a CTOR chart. The only trustworthy data available (without paying) is NASDAQ, and it's stale by the time we see it.

https://nasdaqtrader.com/Trader.aspx?id=ShortInterest

The NASDAQ short interest numbers today at market close will be as of June 30, which is stale data. Looks like the shorts were hitting it again on June 13, the last data point from NASDAQ, and if the shorts didn't cover quickly they got burned on THAT gamble.

CTOR could be a good candidate for a short squeeze because of the small float due to high insider ownership.

CTOR....................................................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

$CTOR

CTOR...................................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

$CTOR: there you go.. now $4.50 !!!!!!!!

Gave you another Banger entry at $3

Just saying.

Tell me I'm wrong............. cuz you CAN'T !!!!!!!!!


GO $CTOR

CTOR...............................................p/m

$CTOR: Undervalued here at $3................

Lots of catchup to do just eyeballing the chart.

TA setup is ideal for move to $15

GO $CTOR

Buy some after offering for commercial launch..
..As of March 31, 2025, the Company had $112 in cash and cash equivalents and 71,552,402 common shares outstanding. Citius Oncology will need to secure additional capital to support operations beyond May 2025...

Looking good.. These efforts are pivotal as we transition into a commercial-stage company and believe the planned 2025 launch of LYMPHIR has the potential to be an important inflection point for both the company and the CTCL community," added Mazur.Manufacturing and Supply Chain ReadinessCitius Oncology has completed commercial-scale manufacturing of LYMPHIR, with packaged and labeled inventory now held at a leading global Contract Development and Manufacturing Organization (CDMO). Sufficient inventory has been manufactured, with a product shelf life of 60 months, to meet projected demand for 12 to 18 months post-launch.Citius Oncology has executed one and is finalizing other distribution services agreements with multiple top-tier global pharmaceutical logistics partners to support broad access and timely delivery across the United States. These agreements are intended to provide access for CTCL patients so that they may be treated at both major cancer centers and within the community setting....

CTOR..................................................................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

ctor......................................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

product launch can't be far away.

Probable reason for the buying interest and price spike in 03/31: Agreement on March 28 for the debt owed to Eisai Co., Ltd.

https://archive.fast-edgar.com/20250403/AL22722CLM226T4Z2I2E2ZY2WSIMC222Z272/

SOMEBODY sure wants some CTOR today.

CTOR.........................................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

That was announced on 2/6/2025. Nothing new.

https://www.otcmarkets.com/filing/html?id=18162539&guid=Xkh-kWtVKkAVBBh

$CTOR: News is out...................

Now $1.35 in PreMarket

[img]http://pbs.twimg.com/media/GnPX_GSXYAAM5fU?format=jpg&name=medium[/img



GO $CTOR

Citius parent company annual meeting March 10.... shareholders rejected the increase in A/S. Our stockholders did not approve the proposal to amend our Articles of Incorporation to increase the authorized number of shares from 26,000,000 to 260,000,000 and the authorized number of common shares from 16,000,000 to 250,000,000. The vote was 3,222,490 shares for, 1,934,414 shares against, 35,367 shares abstaining, and no broker non-votes. https://www.otcmarkets.com/filing/html?id=18271247&guid=qeB-kWXaHcmKdth

CTOR, on the other hand, is going to get the A/S increase from 100M to 400M.The attached Information Statement describes the Certificate of Amendment approved by Stockholder Written Consent, which will increase the Company’s authorized shares of Common Stock to 400,000,000 shares from 100,000,000 shares of Common Stock. https://www.otcmarkets.com/filing/html?id=18215707&guid=qeB-kWXaHcmKdth

That's cool! My wife does research and gets published in journals.... not medical journals, but I understand the process.

You said you got into CTOR too early.... well I'm chasing it now because I tried to lowball that recent dip and missed it.

I played with CTXR a little bit in the last year but didn't do much better than break-even because the shorts still have control of that one and it was difficult dancing around that reverse split.

I usually hate it when tickers like CTXR spin off their tech into subsidiaries because it usually screws the shareholders, but this one is kind of rare in that the subsidiary is public too, and I like the insider ownership here. We've all learned that insider ownership is no guarantee of success, but it sure doesn't hurt!

Cheers, and best of luck!

I was following another stock that got 200 million, but they hadn't met all conditions. My wife writes grant applications, usually gets them, if they had a grant in mind it's worth the effort. Even small grants add up.

That's too bad, because CTOR could use the money from a grant.

Thanks!

It's already reversing so it may steadily go up as start nears. Good buy in price I would think. I bought in too high, but analyst prediction was 6 dollars, and still is.

So my buy could still make money, wait and see.

I think I was thinking of a different company that a grant finalized.

The company said they expect first sales in the first HALF of 2025, not in the first quarter.

True, the first quarter is IN the first half..... but I don't expect the launch until May or June. In biotech, when they say they "expect" something in the first half of a given year, it usually doesn't happen early.

What grant do they "need to finalize?" Can you provide more detail? I know about the NJ grant in March 2024 for $2.4M -- is there another one pending in 2025?

https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-secures-2-4-million-through-new-jersey-economic-development-program-302081639.html

I think the PPS is in a free-fall since Feb 24 because the Form 14 they filed on Feb 24 says they are increasing the A/S from 100M to 400M. Anticipated effective date: April 7th.

I doubt the insiders are dumping -- they paid over $2 per share and THEY are the ones who voted for the A/S increase (Directors, majority shareholders). I think that if they wanted to dump they would have done so before they decided to increase the A/S. Also, I believe all their options are priced higher than the current PPS.

Funding is a problem here, IMO. This company burned $6M last quarter and they have no cash ($112). Per the 10-Q, "The Company plans to continue to rely on funding from Citius Pharma." CTXR isn't rich either (about $1M in cash) and THEY burned $10M last quarter.

Citius expects to launch LYMPHIR in the first half of 2025 and they already have a Medicare J-Code so that is good. Looks like CTOR has a large inventory ($14M) ready to sell ("Inventory consists of finished goods of $6,134,895, and work in process of $8,246,474 as of December 31, 2024"). The question is going to be: how fast can they sell that inventory?

And when will Dr. Reddy's demand that $22M milestone payment? It's already past due. Maybe they are planning to pay Dr. Reddy in stock. From the 10-Q:At the time of the FDA approval for LYMPHIR, a $27.5 million milestone payment became payable under the terms of the asset purchase agreement for which a balance of $22.5 million remains due as of December 31, 2024. Pending further discussions with Dr. Reddy’s, Dr. Reddy’s agreed to a partial deferral without penalty of this milestone payment.

Maybe dilution to pay for everything to get it off the ground., ten dollars this year, maybe so.

Can't tell if stock is falling to let someone buy in or if just no support. Could be a buying opportunity. They need to finalize the grant it seems.

Quite possible, however:

Only if they sucessfully commercially launch their product LYMPHIR which they said will be in the ist half of 2025.

The reason it is so low, is the fact that the 92.2% owner of CTXR ( which spun off CTOR) board of directors is the same board of CTOR, and the CEO is the same. Whom IMO is a very poor manager and he is known to always move the goal posts further and further out.

CTXR the 92.2% owner (controlling CTOR) stock is selling at the lowest in it's history (split basis) due to the CEO's very bad management.

Also funding is a problem.

Anyone think this can hit ten dollars in 2025

CTOR...$1.23...🥳... https://schrts.co/ICqtBicz ...Bollie Squeeze is on...she gonna go up or down...

georgie18

Member Level
Re: georgie18 post# 388659

Thursday, January 16, 2025 3:28:33 PM

Post#
388694
of 390113
CTOR...$1.31...🥳...Trying for Upper Bollie Breakout...

georgie18

Member Level
Re: georgie18 post# 671469

Thursday, January 16, 2025 10:10:25 AM

Post#
671513
of 671603
CTOR...$1.13...🥳... https://schrts.co/gcbJpQsR ...Adding here on the Bullish Kicking Reversal Pattern...

georgie18

Member Level
Re: georgie18 post# 388592

Thursday, January 16, 2025 6:58:32 AM

Post#
388610
of 388659
CTOR...$1.28...🥳...Off my $1.09 Alert...

georgie18

Member Level
Re: None

Wednesday, January 15, 2025 2:15:10 PM

Post#
671415
of 671468
CTOR...Scaling in here on the $1.09 dip...🥳...Like the forward looking event...

CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025.

Thank you

The insider is CTXR the company that spun off CTOR. CTXR owns 92.3% of CTOR.

$CTOR How can this be a spam when insiders own more then 90% of the shares. They know something. CTOR Not to many shares left in the market. Should go up real fast when good news comes out. And it should be soon.
Shares Outstanding
71.55M
Public Float
3.93M

nice summary, launch any day now imo.

Post from MOMO's board, "Up and coming giant:

Citius Oncology (Nasdaq: CTOR)

"Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025."

LYMPHIR ( approved by the FDA for commercialization) is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175721086&txt2find=ctor

trying coiled up trying to break out of this range, can follow like the other one.

Yes Indeed...🥳

CTOR last Aug. 6th the price was $49.00 now $1.32

CTOR Not to many shares left in the market. Should go up real fast when good news comes out.
Total Insider Shares Held 64.72M
Citius Oncology Annual Shares Outstanding
(Millions of Shares)
2024 68M

Post from Stocktwits "$CTOR 400 million estimate for first release to market, this is with a majority still not set to offer lymphir as treatment. They have to as lymphir is the only approved treatment now for su sidies and so on. 400m initial. Insane, ez billion dollars valuation in 2 years time.

1.40's up :)

Demand growing into close,after mkt could be good